Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track BIIB with free AI briefings, catalyst countdowns, and dilution alerts.

BIIB — BIOGEN INC.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$2.9B Cash on Hand

CF+ Cash Runway

4.1% Short Interest

🧪 Upcoming Trial Catalysts

2026-09-30 · N/A — Active Trial — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women Durin
2026-10-20 · Phase 2, Phase 3 — Recruiting — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of A
2026-10-20 · Phase 2, Phase 3 — Active Trial — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of A
2026-10-31 · N/A — Active Trial — A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registrie
2026-12-01 · Phase 3 — Active Trial — A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With
2026-12-07 · N/A — Recruiting — Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

📊 Drug Pipeline

Drug	Indication	Phase	Status
Omeveloxolone	Friedreich's Ataxia	NA	NOT_YET_RECRUITING
Tofersen	Amyotrophic Lateral Sclerosis	PHASE4	ACTIVE_NOT_RECRUITING
Omaveloxolone	Friedreich Ataxia	PHASE3	RECRUITING
Interferon β-1a	Relapsing-Remitting Multiple Sclerosis	PHASE3	COMPLETED
Lecanemab	Preclinical Alzheimer's Disease	PHASE3	ACTIVE_NOT_RECRUITING
Fingolimod	Relapsing Forms of Multiple Sclerosis	PHASE3	NOT_YET_RECRUITING
Felzartamab	Antibody-mediated Rejection	PHASE3	ACTIVE_NOT_RECRUITING
Diroximel Fumarate	Relapsing Forms of Multiple Sclerosis	PHASE3	NOT_YET_RECRUITING
Lecanemab IV	Early Alzheimer's Disease	PHASE3	ACTIVE_NOT_RECRUITING
Dimethyl Fumarate	Relapsing-Remitting Multiple Sclerosis	PHASE3	COMPLETED

💰 Cash Runway & Dilution Risk

BIIB holds $2.9B in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for BIIB free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-08-05	Minor Lloyd	Sale	$667,362
2026-08-05	Minor Lloyd	Sale	$540,381
2026-06-11	SHERWIN STEPHEN A	Purchase	$0
2026-06-11	HAWKINS WILLIAM A	Purchase	$0
2026-06-11	Rowinsky Eric K	Purchase	$0

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2026-05-24	—	NDA	+3.1%	-0.4%	-0.8%
2026-04-03	—	NDA	-6.6%	-2.8%	-2.5%

Browse all historical PDUFA outcomes →

Get the full BIIB picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for BIIB and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z